Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSS06 versus epoetin alfa for chemotherapy-induced anemia in non-myeloid malignancies
CTR20250435Phase 2Active
- Sponsor
- 3SBio
- Start
- Mar 2025
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SSS06 in chemotherapy-induced anaemia (CIA) and nonmyeloid cancer (2 arms), sponsored by 3SBio. Primary endpoint: Safety. Started Mar 2025; status: active.
02
Drugs
SSS06
03
Conditions
chemotherapy-induced anaemia (CIA)nonmyeloid cancer
Beyond the preview
Go deeper on CTR20250435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250435.